Vir Biotechnology, Inc. Overview
Pro stress-test →Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company is positioning itself as a leader in masked T-cell engager immunotherapy while maintaining its hepatitis delta franchise.
Strategic Profile
Pro stress-test →The company has executed two landmark collaborations worth up to $2.2 billion combined. In April 2026, the global strategic collaboration with Astellas to advance the PSMA-targeted dual-masked T-cell engager VIR-5500 closed with the first patient dosed in Phase 1 dose-expansion cohorts. Strategic partnerships and financing have extended cash runway to 2028.
Competitive Landscape
Pro stress-test →Competitors include Rigel Pharmaceuticals, Allogene Therapeutics, Adaptimmune Therapeutics, Sorrento Therapeutics, and Synlogic. Vir differentiates itself through its dual masked T-cell engager platform across both infectious disease and oncology indications, with particularly strong clinical progress in hepatitis delta and prostate cancer.
Industry Context
Vir Biotechnology, Inc. operates in Biopharmaceutical/Immunotherapy.
Key facts
Headquarters: San Francisco, US · Revenue: $64.7 million trailing twelve-month revenue as of March 31, 2026 · Market cap: $1.56 billion as of May 7, 2026